Glimmer is pioneering novel and wildtype-sparing pan-KRAS-mutant therapeutics while avoiding the traditional resistance seen with other KRAS approaches. We are focused on KRAS’s Achilles heel, co-opting the cell membrane in order to proliferate and signal, to disrupt and degrade mutant-KRAS. Backed by novel biology, this first-in-class oral-degrader mechanism uniquely targets all mutant forms of KRAS potentially treating patients resistant to KRAS inhibitors and when combined with these direct inhibitors, deliver a step-change in response and durability.
Company Details
- Address
- Chicago, Il, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Chicago, IL
Glimmer Therapeutics Questions
Glimmer Therapeutics's LinkedIn profile is https://www.linkedin.com/company/glimmertx
Glimmer Therapeutics's industry is
Biotechnology Research
Glimmer Therapeutics's top competitors are
Flatiron Bio,
Enzyme By Design,
Riptide Bioscience, Inc.,
Snc Therapeutics, Inc.,
Ikaika Therapeutics,
Grove Biopharma, Inc.,
101 Therapeutics,
Inomagen Therapeutics,
Bluegrass Pharmaceuticals,
Dimension Bio.
Glimmer Therapeutics's categories are Biotechnology Research
